A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss et al., Decline in the AIDS and death rates in the EuroSIDA study: an observational study, The Lancet, vol.362, issue.9377, pp.22-29, 2003.
DOI : 10.1016/S0140-6736(03)13802-0

F. Palella, . Jr, K. Delaney, A. Moorman, M. Loveless et al., Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.338, issue.13, pp.853-860, 1998.
DOI : 10.1056/NEJM199803263381301

P. Braitstein, M. Brinkhof, F. Dabis, M. Schechter, A. Boulle et al., Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincome countries, Lancet, vol.367, pp.817-824, 2006.

U. Who and . Unicef, Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress report, 2010.

N. Lohse, A. Hansen, G. Pedersen, G. Kronborg, J. Gerstoft et al., Survival of Persons with and without HIV Infection in Denmark, 1995???2005, Annals of Internal Medicine, vol.146, issue.2, pp.87-95, 1995.
DOI : 10.7326/0003-4819-146-2-200701160-00003

J. Neuhaus, B. Angus, J. Kowalska, L. Rosa, A. Sampson et al., Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV, AIDS, vol.24, issue.5, pp.697-706, 2010.
DOI : 10.1097/QAD.0b013e3283365356

N. Friis-moller, C. Sabin, R. Weber, A. Monforte, W. El-sadr et al., Combination antiretroviral therapy and the risk of myocardial infarction, pp.1993-2003, 2003.

J. Neuhaus, D. Jacobs, . Jr, J. Baker, A. Calmy et al., Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection, The Journal of Infectious Diseases, vol.201, issue.12, pp.1788-1795, 2010.
DOI : 10.1086/652749

N. Friis-moller, R. Weber, P. Reiss, R. Thiebaut, O. Kirk et al., Cardiovascular disease risk factors in HIV patients ??? association with antiretroviral therapy. Results from the DAD study, AIDS, vol.17, issue.8, pp.1179-1193, 2003.
DOI : 10.1097/00002030-200305230-00010

S. Deeks and A. Phillips, HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity, BMJ, vol.338, issue.jan26 2, p.3172, 2009.
DOI : 10.1136/bmj.a3172

J. Bongaarts and M. Over, Global HIV/AIDS Policy in Transition, Science, vol.328, issue.5984, pp.1359-1360, 2010.
DOI : 10.1126/science.1191804

A. Karim, Q. , A. Karim, S. Frohlich, J. Grobler et al., Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women, Science, vol.329, issue.5996, pp.1168-1174, 2010.
DOI : 10.1126/science.1193748

B. Auvert, D. Taljaard, E. Lagarde, J. Sobngwi-tambekou, R. Sitta et al., Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial, PLoS Medicine, vol.15, issue.11, p.298, 2005.
DOI : 10.1371/journal.pmed.0020298.st003
URL : https://hal.archives-ouvertes.fr/inserm-00700701

R. Hecht, L. Bollinger, J. Stover, W. Mcgreevey, F. Muhib et al., Critical Choices In Financing The Response To The Global HIV/AIDS Pandemic, Health Affairs, vol.28, issue.6, pp.1591-1605, 2009.
DOI : 10.1377/hlthaff.28.6.1591

T. Chun, L. Carruth, D. Finzi, X. Shen, J. Digiuseppe et al., Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, Nature, vol.387, issue.6629, pp.183-188, 1997.
DOI : 10.1038/387183a0

D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick et al., Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, Nat Med, vol.5, pp.512-517, 1999.

J. Wong, M. Hezareh, H. Gunthard, D. Havlir, C. Ignacio et al., Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia, Science, vol.278, issue.5341, pp.1291-1294, 1997.
DOI : 10.1126/science.278.5341.1291

S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G. Hanna et al., Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy, Proceedings of the National Academy of Sciences, vol.105, issue.10, pp.3879-3884, 2008.
DOI : 10.1073/pnas.0800050105

F. Maldarelli, S. Palmer, M. King, A. Wiegand, M. Polis et al., ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia, PLoS Pathogens, vol.37, issue.4, p.46, 2007.
DOI : 10.1371/journal.ppat.0030046.sg002

S. Sonza, H. Mutimer, R. Oelrichs, D. Jardine, K. Harvey et al., Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy, AIDS, vol.15, issue.1, pp.17-22, 2001.
DOI : 10.1097/00002030-200101050-00005

P. Gorry, D. Purcell, J. Howard, and D. Mcphee, Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication, Journal of Neurovirology, vol.4, issue.4, pp.377-386, 1998.
DOI : 10.3109/13550289809114536

M. Churchill, S. Wesselingh, D. Cowley, C. Pardo, J. Mcarthur et al., Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia, Annals of Neurology, vol.39, issue.2, pp.253-258, 2009.
DOI : 10.1002/ana.21697

J. Zack, A. Haislip, P. Krogstad, and I. Chen, Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle, J Virol, vol.66, pp.1717-1725, 1992.

N. Chomont, M. El-far, P. Ancuta, L. Trautmann, F. Procopio et al., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation, Nature Medicine, vol.45, issue.8, pp.893-900, 2009.
DOI : 10.1038/nm.1972

D. Finzi, M. Hermankova, T. Pierson, L. Carruth, C. Buck et al., Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy, Science, vol.278, issue.5341, pp.1295-1300, 1997.
DOI : 10.1126/science.278.5341.1295

J. Siliciano, J. Kajdas, D. Finzi, T. Quinn, K. Chadwick et al., Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells, Nature Medicine, vol.9, issue.6, pp.727-728, 2003.
DOI : 10.1038/nm880

J. Zack, S. Arrigo, S. Weitsman, A. Go, A. Haislip et al., HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure, Cell, vol.61, issue.2, pp.213-222, 1990.
DOI : 10.1016/0092-8674(90)90802-L

. Lewin, Finding a cure for HIV: will it ever be achievable?, Journal of the International AIDS Society, vol.14, issue.1, p.4, 2011.
DOI : 10.1186/1758-2652-14-4
URL : https://hal.archives-ouvertes.fr/inserm-00663685

L. Musey, J. Krieger, J. Hughes, T. Schacker, L. Corey et al., Early and Persistent Human Immunodeficiency Virus Type 1 (HIV???1)???Specific T Helper Dysfunction in Blood and Lymph Nodes following Acute HIV???1 Infection, The Journal of Infectious Diseases, vol.180, issue.2, pp.278-284, 1999.
DOI : 10.1086/314868

Z. Zhang, T. Schuler, M. Zupancic, S. Wietgrefe, K. Staskus et al., Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells, Science, vol.286, issue.5443, pp.1353-1357, 1999.
DOI : 10.1126/science.286.5443.1353

A. Audige, E. Schlaepfer, A. Bonanomi, H. Joller, M. Knuchel et al., HIV-1 Does Not Provoke Alteration of Cytokine Gene Expression in Lymphoid Tissue after Acute Infection Ex Vivo, The Journal of Immunology, vol.172, issue.4, pp.2687-2696, 2004.
DOI : 10.4049/jimmunol.172.4.2687

D. Eckstein, M. Penn, Y. Korin, D. Scripture-adams, J. Zack et al., HIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues, HIV-1 Actively Replicates in Naive CD4(+) T Cells Residing within Human Lymphoid Tissues, pp.671-682, 2001.
DOI : 10.1016/S1074-7613(01)00217-5

S. Saleh, A. Solomon, F. Wightman, M. Xhilaga, P. Cameron et al., CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency, Blood, vol.110, issue.13, pp.4161-4164, 2007.
DOI : 10.1182/blood-2007-06-097907

P. Cameron, S. Saleh, G. Sallmann, A. Solomon, F. Wightman et al., Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton, Proceedings of the National Academy of Sciences, vol.107, issue.39, pp.16934-16939, 2010.
DOI : 10.1073/pnas.1002894107

A. Bosque and V. Planelles, Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells, Blood, vol.113, issue.1, pp.58-65, 2009.
DOI : 10.1182/blood-2008-07-168393

A. Marini, J. Harper, and F. Romerio, An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency, The Journal of Immunology, vol.181, issue.11, pp.7713-7720, 2008.
DOI : 10.4049/jimmunol.181.11.7713

H. Yang, S. Xing, L. Shan, O. Connell, K. Dinoso et al., Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation, Journal of Clinical Investigation, vol.119, pp.3473-3486, 2009.
DOI : 10.1172/JCI39199DS1

D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick et al., Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, Nat Med, vol.5, pp.512-517, 1999.

D. Brooks, S. Kitchen, C. Kitchen, D. Scripture-adams, and J. Zack, Generation of HIV latency during thymopoiesis, Nature Medicine, vol.7, issue.4, pp.459-464, 2001.
DOI : 10.1038/86531

C. Carter, A. Onafuwa-nuga, L. Mcnamara, R. Jt, D. Bixby et al., HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs, Nature Medicine, vol.142, issue.4, pp.446-451, 2010.
DOI : 10.1038/nm.2109

F. Wightman, A. Solomon, G. Khoury, J. Green, L. Gray et al., Both CD31-positive and CD31-negative naive CD4 T-cells are persistent HIV-infected reservoirs in individuals receiving antiretroviral therapy, J Infect Dis, 2010.

A. Sedaghat, J. Siliciano, T. Brennan, C. Wilke, and R. Siliciano, Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART, PLoS Pathogens, vol.367, issue.8, p.122, 2007.
DOI : 10.1371/journal.ppat.0030122.sd002

T. Brennan, J. Woods, A. Sedaghat, J. Siliciano, R. Siliciano et al., Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy, Journal of Virology, vol.83, issue.17, pp.8470-8481, 2009.
DOI : 10.1128/JVI.02568-08

M. Hermankova, S. Ray, C. Ruff, M. Powell-davis, R. Ingersoll et al., HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy, JAMA, vol.286, issue.2, pp.196-207, 2001.
DOI : 10.1001/jama.286.2.196

D. Persaud, G. Siberry, A. Ahonkhai, J. Kajdas, D. Monie et al., Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads, Journal of Virology, vol.78, issue.2, pp.968-979, 2004.
DOI : 10.1128/JVI.78.2.968-979.2004

M. Churchill, P. Gorry, D. Cowley, L. Lal, S. Sonza et al., Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues, Journal of Neurovirology, vol.12, issue.2, pp.146-152, 2006.
DOI : 10.1080/13550280600748946

T. Chun, D. Nickle, J. Justement, J. Meyers, G. Roby et al., Persistence of HIV in Gut???Associated Lymphoid Tissue despite Long???Term Antiretroviral Therapy, The Journal of Infectious Diseases, vol.197, issue.5, pp.714-720, 2008.
DOI : 10.1086/527324

P. Halfon, C. Giorgetti, H. Khiri, G. Penaranda, P. Terriou et al., Semen May Harbor HIV Despite Effective HAART: Another Piece in the Puzzle, PLoS ONE, vol.47, issue.5, p.10569, 2010.
DOI : 10.1371/journal.pone.0010569.t001

S. Yukl, S. Gianella, E. Sinclair, L. Epling, Q. Li et al., Differences in HIV Burden and Immune Activation within the Gut of HIV???Positive Patients Receiving Suppressive Antiretroviral Therapy, The Journal of Infectious Diseases, vol.202, issue.10, pp.1553-1561, 2010.
DOI : 10.1086/656722

G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation, pp.692-698, 2009.

S. Deeks and B. Walker, Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy, Immunity, vol.27, issue.3, pp.406-416, 2007.
DOI : 10.1016/j.immuni.2007.08.010

P. Hunt, J. Brenchley, E. Sinclair, J. Mccune, R. M. Page-shafer et al., T Cell Count in HIV???Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy, The Journal of Infectious Diseases, vol.197, issue.1, pp.126-133, 2008.
DOI : 10.1086/524143

H. Hatano, E. Delwart, P. Norris, T. Lee, J. Dunn-williams et al., Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy, Journal of Virology, vol.83, issue.1, pp.329-335, 2009.
DOI : 10.1128/JVI.01763-08

F. Pereyra, S. Palmer, T. Miura, B. Block, A. Wiegand et al., Persistent Low???Level Viremia in HIV???1 Elite Controllers and Relationship to Immunologic Parameters, The Journal of Infectious Diseases, vol.200, issue.6, pp.984-990, 2009.
DOI : 10.1086/605446

B. Autran, R. Murphy, D. Costagliola, R. Tubiana, B. Clotet et al., Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452), AIDS, vol.22, issue.11, pp.1313-1322, 2008.
DOI : 10.1097/QAD.0b013e3282fdce94

O. Connell, K. Brennan, T. Bailey, J. Ray, S. Siliciano et al., Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus, Journal of Virology, vol.84, issue.14, pp.7018-7028, 2010.
DOI : 10.1128/JVI.00548-10

J. Dinoso, S. Kim, A. Wiegand, S. Palmer, S. Gange et al., Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy, Proceedings of the National Academy of Sciences, vol.106, issue.23, pp.9403-9408, 2009.
DOI : 10.1073/pnas.0903107106

D. Mcmahon, J. Jones, A. Wiegand, S. Gange, M. Kearney et al., Short???Course Raltegravir Intensification Does Not Reduce Persistent Low???Level Viremia in Patients with HIV???1 Suppression during Receipt of Combination Antiretroviral Therapy, Clinical Infectious Diseases, vol.50, issue.6, pp.912-919, 2010.
DOI : 10.1086/650749

J. Buzon, M. Massanella, J. Llibre, A. Esteve, V. Dahl et al., HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects, Nature Medicine, vol.77, issue.4, pp.460-465, 2010.
DOI : 10.1038/nm.2111

S. Yukl, A. Shergill, K. Mcquaid, S. Gianella, H. Lampiris et al., Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy, AIDS, vol.24, issue.16, pp.2451-2460, 2010.
DOI : 10.1097/QAD.0b013e32833ef7bb

A. Yilmaz, C. Verhofstede, D. Avolio, A. Watson, V. Hagberg et al., Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.55, issue.5, p.16, 2010.
DOI : 10.1097/QAI.0b013e3181f5b3d1

T. Chun, J. Justement, S. Moir, C. Hallahan, J. Maenza et al., Decay of the HIV reservoir in patients Lewin et al, Journal of the International AIDS Society, vol.14, p.4, 2011.

L. Hocqueloux, T. Prazuck, V. Avettand-fenoel, A. Lafeuillade, B. Cardon et al., Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection, AIDS, vol.24, issue.10, pp.1598-1601, 2010.
DOI : 10.1097/QAD.0b013e32833b61ba

M. Bloch, D. Smith, D. Quan, J. Kaldor, J. Zaunders et al., The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.2, pp.192-202, 2006.
DOI : 10.1097/01.qai.0000219779.50668.e6

M. Markowitz, J. X. Hurley, A. Simon, V. Ramratnam, B. Louie et al., Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination, The Journal of Infectious Diseases, vol.186, issue.5, pp.634-643, 2002.
DOI : 10.1086/342559

F. Wang, Y. Xu, J. Sullivan, E. Souder, E. Argyris et al., IL-7 is a potent and proviral strain???specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART, Journal of Clinical Investigation, vol.115, issue.1, pp.128-137, 2005.
DOI : 10.1172/JCI200522574

Y. Levy, C. Lacabaratz, L. Weiss, J. Viard, C. Goujard et al., Enhanced T cell recovery in HIV-1???infected adults through IL-7 treatment, Journal of Clinical Investigation, vol.119, pp.997-1007, 2009.
DOI : 10.1172/JCI38052
URL : https://hal.archives-ouvertes.fr/inserm-00484803

I. Sereti, R. Dunham, J. Spritzler, E. Aga, M. Proschan et al., IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection, Blood, vol.113, issue.25, pp.6304-6314, 2009.
DOI : 10.1182/blood-2008-10-186601

S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J. Gatot et al., Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection, PLoS ONE, vol.4, issue.6, p.6093, 2009.
DOI : 10.1371/journal.pone.0006093.s008
URL : https://hal.archives-ouvertes.fr/hal-00464770

J. Bolden, M. Peart, and R. Johnstone, Anticancer activities of histone deacetylase inhibitors, Nature Reviews Drug Discovery, vol.106, issue.9, pp.769-784, 2006.
DOI : 10.1038/nrd2133

H. Prince, M. Bishton, and S. Harrison, Clinical Studies of Histone Deacetylase Inhibitors, Clinical Cancer Research, vol.15, issue.12, pp.3958-3969, 2009.
DOI : 10.1158/1078-0432.CCR-08-2785

G. Lehrman, I. Hogue, S. Palmer, C. Jennings, C. Spina et al., Depletion of latent HIV-1 infection in vivo: a proof-of-concept study, The Lancet, vol.366, issue.9485, pp.549-555, 2005.
DOI : 10.1016/S0140-6736(05)67098-5

N. Archin, J. Eron, S. Palmer, A. Hartmann-duff, J. Martinson et al., Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells, AIDS, vol.22, issue.10, pp.1131-1135, 2008.
DOI : 10.1097/QAD.0b013e3282fd6df4

J. Siliciano, J. Lai, M. Callender, E. Pitt, H. Zhang et al., Stability of the Latent Reservoir for HIV???1 in Patients Receiving Valproic Acid, The Journal of Infectious Diseases, vol.195, issue.6, pp.833-836, 2007.
DOI : 10.1086/511823

N. Sagot-lerolle, A. Lamine, M. Chaix, F. Boufassa, J. Aboulker et al., Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir, AIDS, vol.22, issue.10, pp.1125-1129, 2008.
DOI : 10.1097/QAD.0b013e3282fd6ddc

X. Contreras, M. Schweneker, C. Chen, J. Mccune, S. Deeks et al., Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells, Journal of Biological Chemistry, vol.284, issue.11, pp.6782-6789, 2009.
DOI : 10.1074/jbc.M807898200

N. Archin, A. Espeseth, D. Parker, M. Cheema, D. Hazuda et al., Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid, AIDS Research and Human Retroviruses, vol.25, issue.2, pp.207-212, 2009.
DOI : 10.1089/aid.2008.0191

J. Burnett, K. Lim, A. Calafi, J. Rossi, D. Schaffer et al., Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants, Journal of Virology, vol.84, issue.12, pp.5958-5974, 2010.
DOI : 10.1128/JVI.00161-10

N. Holt, J. Wang, K. Kim, G. Friedman, X. Wang et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo, Nature Biotechnology, vol.11, issue.8, pp.839-847, 2010.
DOI : 10.1038/nbt.1663

D. Digiusto, A. Krishnan, L. Li, H. Li, S. Li et al., RNA-based gene therapy for HIV with lentiviral vectormodified CD34(+) cells in patients undergoing transplantation for AIDSrelated lymphoma, Sci Transl Med, vol.2, pp.36-43, 2010.

W. El-sadr, J. Lundgren, J. Neaton, F. Gordin, D. Abrams et al., CD4 + count-guided interruption of antiretroviral treatment, pp.2283-2296, 2006.